Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain

Award Number: R61AT012544
ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/08/2023
PERIOD OF PERFORMANCE END DATE: 05/31/2024

Group Awards By:

View Award Description

Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain - PROJECT SUMMARY Relevance to public health. Microglia, the inflammatory cells in the brain and spinal cord, participate in the development of neuropathic pain (NeuP) after nerve injury by releasing reactive oxygen species (ROS) and proinflammatory cytokines. NeuP affects >16 million Americans, is associated with a severe reduction in quality of life. NeuP is often refractory to conventional analgesics, and opioids have only limited efficacy increasing the risk of their misuse. Medications not typically used as analgesics are often the first-line treatment of NeuP. How- ever, <50% of patients report pain relief with current treatment, and side effects are common. We offer evidence that suppressing the voltage-gated proton channel (Hv1) in microglia can reduce inflammatory mediators release and attenuate NeuP. We propose to identify small-molecule Hv1 blockers by high-throughput screening (HTS) of plant extracts and botanical compounds as a step toward new drugs for NeuP. Brief background. This application builds on: (i) our publication that Hv1 controls ROS and proinflammatory cytokines release in microglia and contributes to the development of NeuP, (ii) our preliminary finding that C6, a designer peptide blocker of Hv1, suppresses ROS and proinflammatory cytokine release by microglia and atten- uates NeuP after peripheral nerve injury in mice, and (iii) our successful pilot screening of a small compound library and eight exemplar plant extracts using a novel live-cell, fluorescence-based HTS assay. The HTS assay employs a pH-sensitive fluorescent protein genetically linked to the human Hv1 channel (hHv1-VFP-H148G), allowing real-time monitoring of Hv1 operation and the identification of Hv1 blockers. Unique features and innovation. Our target choice is innovative because no clinically approved drugs se- lectively target microglia and Hv1 lacks potent and specific small-molecule blockers. Our HTS assay is innovative because there is no reported HTS method for proton channels. We identified unique reagents: C6 (the first specific blocker of Hv1), C6 variants, F6 (a small molecule that inhibits Hv1 in the HTS), and Lavender (a plant extract that inhibits Hv1 in the HTS) to facilitate the development, refinement, and validation of the HTS assay. We will employ the HTS assay to screen a unique plant extract library with >1,500 species (with >15,000 esti- mated compounds), many of which have been used historically for anti-inflammation and pain-relief. Three specific aims. (1) Optimize the HTS assay (R61 phase) seeks to improve and validate the HTS assay for plant extracts and botanical compounds. (2) Select leads from a unique library of plant extracts (R33 phase) seeks to screen the plant extracts library and identify potent and specific botanical Hv1 blockers. (3) Study sup- pression of the microglial inflammatory response and NeuP with identified botanical Hv1 blockers (R33 phase) seeks to validate the efficacy of identified botanical Hv1 blockers in microglia cells and a mouse model of NeuP. Significance. This work addresses an unmet medical need for NeuP therapeutics and has a broader influ- ence because Hv1 in microglia is complicit in additional inflammatory disorders, such as ischemic stroke.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	UNIVERSITY OF CALIFORNIA IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Research and Training in Complementary and Integrative Health	000	1	10/15/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $256,401 )
2023	2023	UNIVERSITY OF CALIFORNIA, IRVINE	160 ALDRICH HALL	IRVINE	CA	92697	ORANGE	USA	Research and Training in Complementary and Integrative Health	000	1	6/8/2023	NEW	$256,401
														Subtotal = $256,401

Grand Total All Awards = $256,401

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain

Award Number: R61AT012544

ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/08/2023

PERIOD OF PERFORMANCE END DATE: 05/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer